)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Climb Bio
Climb Bio (CLYM) investor relations material
Climb Bio Oppenheimer 36th Annual Healthcare Life Sciences Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Oppenheimer 36th Annual Healthcare Life Sciences Conference summary25 Feb, 2026
Strategic focus and pipeline overview
Focus on developing differentiated monoclonal antibody therapeutics for immune-mediated diseases, targeting clinically validated pathways such as CD19 and APRIL.
Pipeline includes budoprutug (anti-CD19) and CLYM116 (anti-APRIL), both acquired externally and positioned for overlooked opportunities.
Budoprutug targets B-cell and autoantibody-driven diseases, with a lead indication in primary membranous nephropathy (PMN), and additional programs in ITP and lupus.
CLYM116 is a novel sweeper antibody targeting APRIL, aiming for improved potency and dosing convenience in IgA nephropathy (IgAN).
Subcutaneous formulations are in development to enhance patient and provider flexibility.
Clinical development and data readouts
Phase 1B data for budoprutug in PMN showed profound B-cell depletion and durable remissions, with 60% of patients achieving complete remission up to three years off treatment.
Ongoing phase 2 study in PMN is enrolling, with initial data on B-cell depletion, immunologic response, and proteinuria expected by year-end.
Subcutaneous budoprutug phase 1 healthy volunteer data expected in the first half of the year; CLYM116 healthy volunteer data mid-year.
Initial data from budoprutug in ITP, SLE, and PMN anticipated in the second half of the year.
Preclinical studies of CLYM116 showed superior IgA reduction and longer half-life compared to Sibeprenlimab, supporting potential for less frequent dosing.
Market positioning and competitive landscape
Budoprutug is differentiated from existing CD19 therapies (e.g., UPLIZNA) by offering a subcutaneous option and leveraging learnings to accelerate pivotal trials.
Antibody approach seen as safer and more broadly applicable than cell therapies like CAR-T, which are reserved for severe cases.
CLYM116 aims to address efficacy, convenience, and safety gaps in the evolving IgAN treatment landscape, with a focus on monotherapy but openness to future combinations.
The company is positioned to independently advance pivotal trials in core indications, with potential for partnerships in broader or more complex indications.
Financial runway extends into 2028, with flexibility to raise additional funds for pivotal trials and expanded indications.
CLYM116: What market advantage from PK/PD?
Budoprutug: How to compete with CAR-T and UPLIZNA?
When would Climb pursue partnerships for assets?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Climb Bio earnings date
Leerink Global Healthcare Conference 20269 Mar, 2026
Climb Bio
Next Climb Bio earnings date
Leerink Global Healthcare Conference 20269 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Eliem Therapeutics, Inc. is a biotechnology company focused on developing therapies for neuronal excitability disorders, which are associated with conditions like chronic pain, epilepsy, depression, and anxiety. The company’s approach involves advancing clinical-stage compounds that target neurological diseases, aiming to address significant unmet medical needs. Eliem Therapeutics is headquartered in Wilmington, Delaware, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage